期刊文献+

212例他莫昔芬不良反应回顾性分析 被引量:20

Retrospective study of 212 cases of adverse drug reactions induced by tamoxifen
下载PDF
导出
摘要 目的:探讨他莫昔芬的不良反应特点及其临床表现,为临床监测其不良反应并避免严重不良后果提供参考。方法:通过检索"中国期刊全文数据库"、"万方数据库"等,收集2000–2010年国内医药学期刊发表的他莫昔芬的不良反应文献报道,分别从患者性别与年龄的分布、用药情况、ADR发生时间、ADR累及器官或系统及临床表现等方面进行整理分析。结果:共检索到47篇相关文献,涉及212例病例,51~60岁患者服用他莫昔芬剂量超过20 mg.d-1时不良反应发生率最高。他莫昔芬引起的子宫内膜损害最为多见,其次为肝、眼等器官损害,其他不良反应散在发生。结论:在临床应用过程中,应关注他莫昔芬引起的不良反应,可以通过对患者用药过程进行监护等措施确保患者用药安全。 Objective: To investigate the clinical manifestations and characteristics of ADRs induced by tamoxifen,and provide reference for monitoring and avoiding serious ADRs.Methods: The literatures between 2000 and 2010 were retrieved from" Chinese Academic Journal" and" Wafang Database",the data in respect of distribution of gender and age,the situation of medication,occurrence time of ADR,organs or systems involved in ADRs and clinical manifestations were analyzed.Results: Forty seven articles were collected,and 212 cases were involved in.The occurrence of ADRs in the patients whose ages were between 51 and 60 years and whose doses were over 20 mg.d-1 was high.The endometrial damages induced by tamoxifen in postmenopausal women were the most common ADR,followed by the damage of the liver and eye.Conclusion: Treatment with tamoxifen should be monitored closely.Stop taking tamoxifen at once if the serious ADRs occurred.Symptomatic treatments should be given to avoid serious adverse events.Monitoring the process of medication can be used to ensure medication safety.
出处 《中国药物应用与监测》 CAS 2011年第6期366-368,共3页 Chinese Journal of Drug Application and Monitoring
基金 卫生公益性行业科研专项经费项目(200902008-03)
关键词 他莫昔芬 药品不良反应 子宫内膜损害 回顾性分析 Tamoxifen Adverse drug reaction Endometrial damage Retrospective analysis
  • 相关文献

参考文献11

  • 1陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011.81.
  • 2李振新.他莫昔芬的不良反应[J].中国药业,2001,10(4):54-56. 被引量:5
  • 3高婉丽,冯力民,王伟娟,李晶华,刘小春.绝经后乳腺癌患者服用他莫昔芬发生子宫内膜息肉危险因素的探讨[J].现代妇产科进展,2005,14(4):289-292. 被引量:6
  • 4王敏,惠京.他莫昔芬对子宫内膜细胞的影响及其作用机制[J].国外医学(妇产科学分册),2007,34(1):66-69. 被引量:4
  • 5Wilder JL, Shajahan S, Khattar NH, et al.Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study[J], Gynecol Oncol, 2004, 92(2): 553-558.
  • 6Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment[J]. Gynecol Oncol, 2004, 94(2): 256-266.
  • 7Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen[J]. Gynecol Oncol, 2003, 91:154-159.
  • 8Cohen I, Azaria R, Bernheim J, et al. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen[J]. Cancer, 2001, 92(5): 1151 - 1155.
  • 9李宏,姜继勇.他莫昔芬与子宫内膜癌[J].国外医学(妇产科学分册),2005,32(3):189-191. 被引量:4
  • 10Egawa T, Toda K, Nemoto Y, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient(Ar-/-) mice[J]. Lipids, 2003, 38(5): 519-523.

二级参考文献73

  • 1裘乾金.三苯氧胺治疗乳腺癌诱发子宫内膜增生过长一例[J].中华妇产科杂志,1996,31(2):116-116. 被引量:2
  • 2常青.三苯氧胺治疗无症状绝经后乳腺癌时患者子宫内膜组织学的不同特点[J].国外医学.妇产科学分册,1998,25(3):189-189.
  • 3吕平 周应芳(译).三苯氧胺治疗绝经前后乳腺癌妇女其卵巢囊肿发病情况[J].国外医学:妇产科学分册,1997,24:60-61.
  • 4孙定人 王士凡 王功立.药物不良反应[M](第2版)[M].北京:人民卫生出版社,1998.16-17.
  • 5Fisher B,Costantino JP,Redmond CK,et al.Endometrial cancer in tamoxifen treated breast cancer patients : findings from the National Surgical Adjuvant Breast and Bowel project (NASBP) B-14. J Natl Cancer Inst,1994,86(7):527-537.
  • 6Cohen I.Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol,200d,94(2):256-266.
  • 7Hachisuga T,Saito T,Kigawa J,et al. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.Gynecol Oncol, 2004, 95(1):139-144.
  • 8Mourits M, Hoot K,Vanderzee A. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol,2002,55(7):514-519.
  • 9Mourits M,Hollema H,Devries E. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol, 2002.33(3) : 341-346.
  • 10Mullauer L, Mosberger I,Grusch M,et al.Fas ligand is expressed in normal breast epithelial cells and is frequently upregulated in breast cancer. J Pathol,2000,190(1):20-30.

共引文献107

同被引文献260

引证文献20

二级引证文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部